Global Candidiasis Therapeutics Market, By Type Oropharyngeal Candidiasis, Genital Candidiasis, Invasive Candidasis and Others), Symptom Type (Oral Thrush, Fatigue, Urinary Tract Infection (UTI) and Others), Treatment Type (Medication, Surgery and Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights : Global Candidiasis Therapeutics Market
The candidiasis therapeutics market is expected to witness market growth at a rate of 5.10% in the forecast period of 2021 to 2028. Data Bridge Market Research report on candidiasis therapeutics market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The growth in awareness regarding diseases globally is escalating the growth of candidiasis therapeutics market.
Candidiasis, also called thrush, refers to a fungal infection affecting men and women of all age groups. When thrush extends into the throat, then results into esophagitis. Candidosis, moniliasis, and oidiomycosis are some of the other names of candidiasis. Candidasis is caused by yeasts that belongs to genus Candida.
The increase in number of patients affected by candidiasis infection across the globe acts as one of the major factors driving the growth of candidiasis therapeutics market. The growth in awareness in the developing countries about infections and others diseases associated with candidiasis, and rise in consumer inclination towards maintaining aesthetic appearance accelerate the market growth. The increase in the susceptible immune-compromised patient pool and increase in the rate of acquisition strategies and company collaborations among manufacturers further influence the market. Additionally, rise in investment, rise in geriatric population, increase in fund for research and development activities, and rapid urbanization positively affect the candidiasis therapeutics market. Furthermore, advancements in the therapeutics extend profitable opportunities to the market players in the forecast period of 2021 to 2028.
On the other hand, availability of alternative treatments such as probiotics and limited research and development activities are expected to obstruct the market growth. Competition from herbal medicines is projected to challenge the candidiasis therapeutics market in the forecast period of 2021-2028.
This candidiasis therapeutics market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info candidiasis therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Candidiasis Therapeutics Market Scope and Market Size
The candidiasis therapeutics market is segmented on the basis of type, symptom type, treatment type, mode of administration, distribution channel and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drugs, the candidiasis therapeutics market is segmented into oropharyngeal candidiasis, genital candidiasis, invasive candidasis and others.
- On the basis of symptom type, the candidiasis therapeutics market is segmented into oral thrush, fatigue, urinary tract infection (UTI) and others.
- On the basis of treatment type, the candidiasis therapeutics market is segmented into medication, surgery and others.
- On the basis of mode of administration, the candidiasis therapeutics market is segmented into injectable, oral and others.
- On the basis of distribution channel, the candidiasis therapeutics market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
- On the basis of end user, the candidiasis therapeutics market is segmented into hospitals, homecare, specialty clinics and others.
Candidiasis Therapeutics Market Country Level Analysis
The candidiasis therapeutics market is analyzed and market size information is provided by country, type, symptom type, treatment type, mode of administration, distribution channel and end user as referenced above.
The countries covered in the candidiasis therapeutics market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the candidiasis therapeutics market due to the higher awareness of the disease amongst individuals and also availability of better treatment within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2021 to 2028 because of the low unmet need in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The candidiasis therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Candidiasis Therapeutics Market Share Analysis
The candidiasis therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related candidiasis therapeutics market.
The major players covered in the candidiasis therapeutics market report are Bruker, Cidara Therapeutics, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Pacgen Life Science Corporation, NovaDigm Therapeutics, Amplyx, NovaBiotics Inc, Bayer AG, Teva Pharmaceutical Industries Ltd., WOCKHARDT, Pfizer Inc., GlaxoSmithKline plc, ALLERGAN, AstraZeneca, and Torrent Pharmaceuticals Ltd., among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-